Medtronic plc (MDT) recently shared a comprehensive set of new data emphasizing the benefits of the MiniMed 780G insulin pump system. The latest findings demonstrate how the system addresses hyperglycemia and nighttime burden, adding to the pool of evidence proving the system's ability to tackle the difficulties of diabetes, such as managing highs and meal-time management or carb counting while mirroring outcomes across a diverse population. The company presented the series of data at the American Diabetes ...